

Glenda Gray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9406992/publications.pdf>

Version: 2024-02-01

52
papers

6,258
citations

236925

25
h-index

182427

51
g-index

60
all docs

60
docs citations

60
times ranked

9063
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex work and young women: a cross sectional study to understand the overlap of age and sex work as a central tenet to epidemic control in South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 555-563.	1.2	5
2	Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 494-496.	27.0	570
3	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COVS. <i>New England Journal of Medicine</i> , 2022, 386, 847-860.	27.0	132
4	Allergic reactions to the Ad26.COVS vaccine in South Africa. , 2022, 1, 2-8.		3
5	The HIV Cascade of Care and Service Utilisation at Sex Work Programmes Among Female Sex Workers in South Africa. <i>AIDS and Behavior</i> , 2022, 26, 2907-2919.	2.7	8
6	Effectiveness of the Ad26.COVS vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. <i>Lancet, The</i> , 2022, 399, 1141-1153.	13.7	51
7	High Asymptomatic Carriage With the Omicron Variant in South Africa. <i>Clinical Infectious Diseases</i> , 2022, 75, e289-e292.	5.8	74
8	Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoVS Vaccination in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2022, 75, e857-e864.	5.8	30
9	Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COVS Coronavirus Disease 2019 Vaccine. <i>Journal of Infectious Diseases</i> , 2022, 226, 979-982.	4.0	7
10	Effectiveness of Ad26.COVS and BNT162b2 Vaccines against Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 2243-2245.	27.0	65
11	Randomised trials of COVID-19 vaccines in Africa – charting the path forward. <i>South African Journal of Science</i> , 2022, 118, .	0.7	1
12	Safety evaluation of the single-dose Ad26.COVS vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. <i>PLoS Medicine</i> , 2022, 19, e1004024.	8.4	10
13	Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	4.0	11
14	Estimating the contribution of key populations towards HIV transmission in South Africa. <i>Journal of the International AIDS Society</i> , 2021, 24, e25650.	3.0	28
15	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	27.0	144
16	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	27.0	270
17	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	4.7	19
18	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021, 6, 56.	6.0	7

#	ARTICLE	IF	CITATIONS
19	The path to find an HIV vaccine. <i>Journal of the International AIDS Society</i> , 2021, 24, e25749.	3.0	6
20	Thromboembolic Events in the South African Ad26.CO V2.S Vaccine Study. <i>New England Journal of Medicine</i> , 2021, 385, 570-571.	27.0	42
21	Safety and Efficacy of Single-Dose Ad26.CO V2.S Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201.	27.0	1,954
22	Sexual IPV and non-partner rape of female sex workers: Findings of a cross-sectional community-centric national study in South Africa. <i>SSM Mental Health</i> , 2021, 1, 100012.	1.8	7
23	Community-led cross-sectional study of social and employment circumstances, HIV and associated factors amongst female sex workers in South Africa: study protocol. <i>Global Health Action</i> , 2021, 14, 1953243.	1.9	9
24	Prior infection with SARS-CoV-2 boosts and broadens Ad26.CO V2.S immunogenicity in a variant-dependent manner. <i>Cell Host and Microbe</i> , 2021, 29, 1611-1619.e5.	11.0	106
25	An HIV Vaccine Protective Allele in FCGR2C Associates With Increased Odds of Perinatal HIV Acquisition. <i>Frontiers in Immunology</i> , 2021, 12, 760571.	4.8	2
26	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , 2020, 10, 13031.	3.3	10
27	Review of preventative HIV vaccine clinical trials in South Africa. <i>Archives of Virology</i> , 2020, 165, 2439-2452.	2.1	18
28	Exploring potential of vaginal <i>Lactobacillus</i> isolates from South African women for enhancing treatment for bacterial vaginosis. <i>PLoS Pathogens</i> , 2020, 16, e1008559.	4.7	31
29	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	8.4	27
30	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	3.3	17
31	Implementation of a PMTCT programme in a high HIV prevalence setting in Johannesburg, South Africa: 2002-2015. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1024.	0.9	9
32	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	46
33	Recreational ART use among individuals living with HIV/AIDS in South Africa: Examining longitudinal ART initiation and viral suppression. <i>Drug and Alcohol Dependence</i> , 2019, 198, 192-198.	3.2	7
34	HIV research in South Africa: Advancing life. <i>South African Medical Journal</i> , 2019, 109, 36.	0.6	6
35	Microbial Composition Predicts Genital Tract Inflammation and Persistent Bacterial Vaginosis in South African Adolescent Females. <i>Infection and Immunity</i> , 2018, 86, .	2.2	136
36	Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. <i>International Journal of STD and AIDS</i> , 2018, 29, 531-539.	1.1	48

#	ARTICLE	IF	CITATIONS
37	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	4.7	86
38	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet</i> , 2018, 392, 232-243.	13.7	269
39	Depression and Post Traumatic Stress amongst female sex workers in Soweto, South Africa: A cross sectional, respondent driven sample. <i>PLoS ONE</i> , 2018, 13, e0196759.	2.5	32
40	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
41	Cross-sectional study of female sex workers in Soweto, South Africa: Factors associated with HIV infection. <i>PLoS ONE</i> , 2017, 12, e0184775.	2.5	38
42	HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study. <i>PLoS ONE</i> , 2017, 12, e0188606.	2.5	20
43	Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?. <i>PLoS Biology</i> , 2016, 14, e1002372.	5.6	12
44	Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. <i>Vaccine Journal</i> , 2016, 23, 496-506.	3.1	24
45	Approaches to preventative and therapeutic HIV vaccines. <i>Current Opinion in Virology</i> , 2016, 17, 104-109.	5.4	72
46	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , 2016, 12, e1005742.	4.7	81
47	Exposure to and experiences of violence among adolescents in lower socio-economic groups in Johannesburg, South Africa. <i>BMC Public Health</i> , 2015, 15, 450.	2.9	27
48	Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses. <i>PLoS ONE</i> , 2014, 9, e103446.	2.5	9
49	A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. <i>Statistical Communications in Infectious Diseases</i> , 2011, 3, .	0.2	23
50	A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. <i>Aids</i> , 2005, 19, 1289-1297.	2.2	82
51	Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa. <i>Lancet</i> , 2004, 363, 1415-1421.	13.7	1,041
52	A Multicenter Randomized Controlled Trial of Nevirapine Versus a Combination of Zidovudine and Lamivudine to Reduce Intrapartum and Early Postpartum Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1. <i>Journal of Infectious Diseases</i> , 2003, 187, 725-735.	4.0	328